[go: up one dir, main page]

WO2007025044A8 - Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators - Google Patents

Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Info

Publication number
WO2007025044A8
WO2007025044A8 PCT/US2006/033073 US2006033073W WO2007025044A8 WO 2007025044 A8 WO2007025044 A8 WO 2007025044A8 US 2006033073 W US2006033073 W US 2006033073W WO 2007025044 A8 WO2007025044 A8 WO 2007025044A8
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
methods
growth factor
factor receptor
epidermal growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/033073
Other languages
French (fr)
Other versions
WO2007025044A2 (en
WO2007025044A3 (en
Inventor
Shirin K Ford
Edwin A Clark
Xin Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CA002620195A priority Critical patent/CA2620195A1/en
Priority to US11/990,713 priority patent/US8129114B2/en
Priority to JP2008528150A priority patent/JP2009505658A/en
Priority to AT06813702T priority patent/ATE520979T1/en
Priority to EP06813702A priority patent/EP1917528B1/en
Publication of WO2007025044A2 publication Critical patent/WO2007025044A2/en
Publication of WO2007025044A8 publication Critical patent/WO2007025044A8/en
Publication of WO2007025044A3 publication Critical patent/WO2007025044A3/en
Anticipated expiration legal-status Critical
Priority to US13/372,824 priority patent/US20120195889A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
PCT/US2006/033073 2005-08-24 2006-08-24 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators Ceased WO2007025044A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002620195A CA2620195A1 (en) 2005-08-24 2006-08-24 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US11/990,713 US8129114B2 (en) 2005-08-24 2006-08-24 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
JP2008528150A JP2009505658A (en) 2005-08-24 2006-08-24 Biomarkers and methods for determining susceptibility to epidermal growth factor receptor modulators
AT06813702T ATE520979T1 (en) 2005-08-24 2006-08-24 BIOMARRKERS AND METHODS FOR DETERMINING SENSITIVITY TO MODULATORS OF THE EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR
EP06813702A EP1917528B1 (en) 2005-08-24 2006-08-24 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US13/372,824 US20120195889A1 (en) 2005-08-24 2012-02-14 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71105405P 2005-08-24 2005-08-24
US60/711,054 2005-08-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/372,824 Division US20120195889A1 (en) 2005-08-24 2012-02-14 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Publications (3)

Publication Number Publication Date
WO2007025044A2 WO2007025044A2 (en) 2007-03-01
WO2007025044A8 true WO2007025044A8 (en) 2007-07-05
WO2007025044A3 WO2007025044A3 (en) 2007-09-20

Family

ID=37772388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033073 Ceased WO2007025044A2 (en) 2005-08-24 2006-08-24 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Country Status (7)

Country Link
US (2) US8129114B2 (en)
EP (1) EP1917528B1 (en)
JP (1) JP2009505658A (en)
AT (1) ATE520979T1 (en)
CA (1) CA2620195A1 (en)
ES (1) ES2370054T3 (en)
WO (1) WO2007025044A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506066A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2553264T3 (en) 2004-05-27 2015-12-07 The Regents Of The University Of Colorado Methods for predicting the clinical outcome for epidermal growth factor receptor inhibitors for cancer patients
AU2016250348A1 (en) * 2007-03-13 2016-11-10 Amgen Inc. K-ras mutations and anti-EGFr antibody therapy field
HRP20140360T4 (en) * 2007-03-13 2022-06-10 Amgen, Inc. K-ras mutations and anti-egfr antibody therapy
US8975081B2 (en) 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
FI20070795A0 (en) * 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy A new biomarker for monitoring disease development and assessing the effectiveness of therapies
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
AU2009246398A1 (en) * 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
WO2010065626A1 (en) * 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
WO2010080804A1 (en) * 2009-01-06 2010-07-15 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
SG176773A1 (en) * 2009-06-19 2012-01-30 Merck Patent Gmbh Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
RU2553379C2 (en) * 2009-08-24 2015-06-10 Дженентек, Инк. DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION
US20130035249A1 (en) * 2009-12-01 2013-02-07 Medimmune, Llc Methods and compositions for detecting and treating cea-expressing cancers
JP2013523178A (en) * 2010-04-12 2013-06-17 レスポンス ジェネティクス，インコーポレイティド KRAS primers and probes
CN110711188A (en) 2012-01-20 2020-01-21 德玛公司 Use of substituted hexitols for the treatment of malignant tumors
EP2823307A4 (en) * 2012-03-08 2015-07-29 Bioscale Inc Methods and kits for analyzing biomarkers in a signal transduction pathway
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
EP2891884B1 (en) 2014-01-07 2017-10-25 Samsung Electronics Co., Ltd IL-8 for predicting or monitoring efficacy of c-MET inhibitor
US20150254433A1 (en) * 2014-03-05 2015-09-10 Bruce MACHER Methods and Models for Determining Likelihood of Cancer Drug Treatment Success Utilizing Predictor Biomarkers, and Methods of Diagnosing and Treating Cancer Using the Biomarkers
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
US20160024585A1 (en) * 2014-05-02 2016-01-28 Duke University Methods of predicting responsiveness of a cancer to an agent and methods of determining a prognosis for a cancer patient
KR20160037666A (en) 2014-09-29 2016-04-06 삼성전자주식회사 Prediction of Effect of a c-Met Inhibitor using mutation of KRAS or BRAF
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
US11756655B2 (en) 2015-10-09 2023-09-12 Guardant Health, Inc. Population based treatment recommender using cell free DNA
MA43163A (en) 2015-11-02 2018-09-12 Five Prime Therapeutics Inc CD80 EXTRACELLULAR POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
CN109457052A (en) * 2018-12-18 2019-03-12 苏州德思普生物科技有限公司 Detect primer, probe, kit and the detection method of human immunodeficiency virus nucleic acid
EP4217393A1 (en) * 2020-09-22 2023-08-02 Ventana Medical Systems, Inc. Prediction of response to epidermal growth factor receptor-directed therapies using epiregulin and amphiregulin
CN117964690B (en) * 2024-02-04 2024-07-23 北京榕树堂生物科技有限公司 Bird's nest peptide III with skin elasticity protecting and anti-inflammatory effects and application thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US6713619B1 (en) * 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5591582A (en) * 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
JPH05506857A (en) 1990-04-16 1993-10-07 ローヌ―プーラン　ローラー　インターナショナル　（ホウルディングス）インコーポレイテッド Styryl-Substituted Monocyclic and Bicyclic Heteroaryl Compounds that Inhibit EGF Receptor Tyrosine Kinase
DK0531472T3 (en) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humanized monoclonal antibodies
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5656655A (en) * 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
DE69536015D1 (en) 1995-03-30 2009-12-10 Pfizer Prod Inc Quinazolinone derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
JP4275733B2 (en) 1996-01-23 2009-06-10 ノバルティス アクチエンゲゼルシャフト Pyrrolopyrimidine and process for producing the same
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6156504A (en) * 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
ES2301194T3 (en) 1997-02-05 2008-06-16 Warner-Lambert Company Llc PIRIDO 2,3-D PYRIMIDINS AND 4-AMINOPIRIMIDINAS AS INHIBITORS OF THE CELL PROLIFERATION.
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP4548642B2 (en) 1998-09-29 2010-09-22 アメリカン・サイアナミド・カンパニー Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
DK1272647T3 (en) * 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
EP1597558A2 (en) 2003-01-08 2005-11-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
KR101126560B1 (en) * 2003-05-30 2012-04-05 도꾜 다이가꾸 Process for predicting drug response
EP1759010A4 (en) * 2004-01-07 2008-12-24 Bristol Myers Squibb Co Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20070259375A1 (en) 2004-03-26 2007-11-08 Bristol-Myers Squibb Company Biomarkers and Methods for Determining Sensitivity to Epidermal Growth Factor Receptor Modulators in Non-Small Cell Lung Cancer
EP2592155B2 (en) * 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
WO2007001868A1 (en) * 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7858389B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
EP2118322A2 (en) * 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
HRP20140360T4 (en) * 2007-03-13 2022-06-10 Amgen, Inc. K-ras mutations and anti-egfr antibody therapy

Also Published As

Publication number Publication date
EP1917528B1 (en) 2011-08-17
ES2370054T3 (en) 2011-12-12
EP1917528A4 (en) 2009-03-11
ATE520979T1 (en) 2011-09-15
WO2007025044A2 (en) 2007-03-01
CA2620195A1 (en) 2007-03-01
US8129114B2 (en) 2012-03-06
US20100221754A1 (en) 2010-09-02
JP2009505658A (en) 2009-02-12
EP1917528A2 (en) 2008-05-07
US20120195889A1 (en) 2012-08-02
WO2007025044A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
WO2007025044A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2004063709A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2008144345A3 (en) Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
MX2007014815A (en) Improved immunoassay methods.
DE602005013225D1 (en) APTAMER NANOPARTICLE CONJUGATES AND USE METHOD FOR THE DETECTION OF TARGET ANALYSTS
WO2010006048A3 (en) Gene expression profiling for predicting the survivability of prostate cancer subjects
WO2008063414A3 (en) Gene expression profiling for identification, monitoring, and treatment of colorectal cancer
WO2007038754A3 (en) Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2005067667A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
ATE452343T1 (en) IMPROVED VITAMIN D MEASUREMENT
WO2007100677A3 (en) Method and device for analyte measurement
IL181132A0 (en) Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system
MX2010003438A (en) Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators.
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
DE60021369D1 (en) METHOD FOR THE EVALUATION OF A TREATMENT RISK
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
WO2007126901A3 (en) Apparatus and method for predicting disease
WO2003016907A1 (en) Reagent for assaying laminin 5 antigen in biological sample and assay method
EP1722229B8 (en) Method of assessing risk of and predisposition to the development of a pathology related to the presence of anti-epcr antibodies
ATE462803T1 (en) KIT AND METHOD FOR DETECTING UROTHELIC CARCINOMA
WO2009082533A3 (en) Method of identification of petroleum compounds using frequency mixing on surfaces
WO2005119209A3 (en) System and method for analyzing microbial growth

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11990713

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2620195

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008528150

Country of ref document: JP

Ref document number: 2006813702

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE